Category: SILQ

WashU, Eisai form drug discovery collaboration (Links to an external site)

Featured image from the linked article

Washington University School of Medicine in St. Louis and the pharmaceutical company Eisai Co. Ltd., headquartered in Japan, have formed a research collaboration aimed at developing new treatments for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions. The two organizations previously have partnered on Alzheimer’s clinical trials, and the new alliance combines their complementary efforts to identify and validate biomarkers and drug targets for a range of neurodegenerative conditions, with a goal of developing new drugs for the benefit of patients worldwide.

New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)

Nicolas Barthélemy, PhD, an assistant professor of neurology at Washington University School of Medicine in St. Louis, loads a sample into a mass spectrometer. Barthélemy uses mass spectrometry as part of his work at the university’s new Tracy Family SILQ Center for Neurodegenerative Biology. The center was established to help researchers discover, study and validate biomarkers of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with a goal of identifying new drug targets and creating better diagnostic and prognostic tests.

A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]

Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)

Featured image from linked article

“A blood test for Alzheimer’s provides a huge boost for Alzheimer’s research and diagnosis, drastically cutting the time and cost of identifying patients for clinical trials and spurring the development of new treatment options,” Bateman said. “As new drugs become available, a blood test could determine who might benefit from treatment, including those at very early stages of the disease.”